Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Assets: 2016-2025

Historic Non-Current Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $140.4 million.

  • Rocket Pharmaceuticals' Non-Current Assets fell 7.62% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.4 million, marking a year-over-year decrease of 7.62%. This contributed to the annual value of $149.5 million for FY2024, which is 20.52% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Non-Current Assets stood at $140.4 million, which was down 2.41% from $143.8 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Non-Current Assets ranged from a high of $188.1 million in Q4 2023 and a low of $104.7 million during Q1 2021.
  • Its 3-year average for Non-Current Assets is $155.1 million, with a median of $151.9 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 78.87% in 2022, then decreased by 20.52% in 2024.
  • Rocket Pharmaceuticals' Non-Current Assets (Quarterly) stood at $105.0 million in 2021, then surged by 78.87% to $187.7 million in 2022, then rose by 0.20% to $188.1 million in 2023, then dropped by 20.52% to $149.5 million in 2024, then decreased by 7.62% to $140.4 million in 2025.
  • Its Non-Current Assets stands at $140.4 million for Q3 2025, versus $143.8 million for Q2 2025 and $146.6 million for Q1 2025.